E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Ebola virus disease (EVD), is a severe, often fatal disease in humans, spread by contact with body fluids. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10014071 |
E.1.2 | Term | Ebola disease |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the long-term persistence of immunity (both cellular immunity and antibody levels) in healthy volunteers who were vaccinated approximately 2-5 years previously with investigational Ebola vaccines (ChAd3-EBO Z, MVA–BN-FILO, MVA-EBO-Z and Ad26.ZEBOV), and to assess the response to a booster dose of an investigational Ebola vaccine (Ad26.ZEBOV) given approximately 2-5 years after the initial vaccines. |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and reactogenicity of a booster dose of an investigational Ebola vaccine (Ad26.ZEBOV).
Vaccine safety refers to the tendency of a vaccine to produce adverse health effects in vaccinated individuals while reactogenicity refers to the extent to which the vaccine causes common expected reactions such as mild pain or swelling at the injection site, tiredness and elevated temperature for a short time period after vaccination. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Participants must have completed an immunisation schedule in one of the following studies led by the Oxford Vaccine Centre; EBL01 (REC14/SC/1256), EBL04 (REC 15/SC/0108) or EBL05 (REC 15/SC/0267) • Willing and able to give written informed consent for participation in the study • In good health as determined by medical history, physical examination and clinical judgment of the investigators • Females of childbearing potential: willing to use effective contraception (the oral contraceptive pill, contraceptive implant, contraceptive injection, intrauterine device, intrauterine hormone-releasing systems (IUS) barrier methods, vasectomized partner or abstinence) from one month prior to three months after the vaccine. Vaccination will be delayed in female participants who have not used effective contraception for one month prior to Visit 1* • Able to attend the scheduled visits and to comply with all study procedures, including internet access for the recording of diary cards* • Willing to allow his or her General Practitioner to be notified of participation in the study • Agree to be registered on the Trial Over-Volunteering Prevention Service (TOPS) and agree to provide their National Insurance number or passport number (if not a British citizen) for the purposes of registration* • Agree to provide National Insurance number and Bank details for reimbursement purposes
* Participants intending to receive booster dose only
|
|
E.4 | Principal exclusion criteria |
• History of malignancy • Pregnancy or breast feeding • New significant medical or surgical history since completion of the previous study (based on participant recall) • Receipt or planned receipt of adeno virus based vaccine since the parent Ebola vaccine studies • Chronic or recurrent use of medication which modify host immune response • Any contraindication to venepuncture, as determined by clinical judgement • History of allergy or anaphylaxis to a vaccine or any component within the vaccines used in this study (booster group only) • Have any known or suspected impairment or alteration of immune function, resulting from, for example: o Congenital or acquired immunodeficiency o Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition o Autoimmune disease o Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy (10mg daily or higher) or any systemic corticosteroid (or equivalent) treatment within 14 days prior to vaccination, or for more than 7 days consecutively within the previous 3 months. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The persistence of humoral and cellular immunity against Ebola virus glycoprotein with or without a booster dose of AD26.ZEBOV administered 2 to 5 years after heterologous prime/boost schedules of adenoviral and MVA vectored Ebola vaccine schedules.
Outcome measures: - Humoral: Ebola GP specific IgG as measured by ELISA 12 months from first visit - Cellular: Ebola GP specific T cell cytokine response measured using ex vivo interferon-y enzyme-linked immunosorbent spot (ELISPOT) 12 months from first visit |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 months from first visit |
|
E.5.2 | Secondary end point(s) |
1. Humoral and cellular immunity against Ebola virus glycoprotein before and after a late booster dose of AD26.ZEBOV administered 2 to 5 years after adenoviral and MVA vectored Ebola vaccine schedules.
2. Humoral and cellular immunity against Ebola virus glycoprotein 2 to 6 years after adenoviral and MVA vectored Ebola vaccine schedules in the absence of a late booster dose.
3. Safety and reactogenicity of late booster dose of AD26.ZEBOV administered 2 to 5 years after adenoviral and MVA vectored Ebola vaccine schedules. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. and 2. Baseline (Visit 1), 7 days and 1 month post immunisation (baseline and 12 months only for those participants opting not to receive a booster vaccine in this study).
3. Days 0-3 post immunisation, Days 0-28 post immunisation and Days 0-365.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 2 |